Erythrocytic membrane anionic charge, sialic acid content, and their correlations with urinary glycosaminoglycans in preeclampsia and eclampsia.

Compared to healthy pregnant women, changes in erythrocytic membrane anionic charge (EAC) and urinary glycosaminoglycans (UGAGS) have been reported in African women with preeclampsia. A single previous study showed a decrease in erythrocytic membrane sialic acid (EMSA) in preeclampsia compared to healthy pregnancy; however, EMSA was not significantly different between women with preeclampsia and non-pregnant women. No study has focused on the relationships between EAC, EMSA, and UGAGS in preeclampsia and eclampsia compared to healthy pregnant and non-pregnant women of reproductive age. Moreover, the erythrocyte membrane contains sialoglycoproteins and proteoglycans involved in creating the negatively charged cell surface, disruption of which leads to erythrocyte aggregation seen in preeclampsia/eclampsia. However, the etiopathogenesis of preeclampsia and eclampsia remains unclear. Therefore, we evaluated the relationship between EAC, UGAGS, and EMSA in preeclampsia and eclampsia. Three groups of 30 women each were enrolled: Group A (non-pregnant women), Group B (healthy pregnant women without complications), and Group C (women with preeclampsia/eclampsia). EMSA was diminished under oxidative stress prevalent in eclampsia and preeclampsia which might have caused a decreased EAC. EAC was negatively correlated with UGAGS and positively correlated with EMSA (p < .001). EMSA was negatively correlated with UGAGS (p < .001). In conclusion, a loss of sialic acid from the erythrocyte membrane causes a significant decrease in the EAC which mirrors the decrease in the negative charge of the renal glomerular basement membrane and might lead to proteinuria and increased UGAGS excretion in preeclampsia and eclampsia.

Graphene oxide nanohybrids for electron transfer-mediated antimicrobial activity.

The rapid increase in the prevalence of antibiotic-resistant bacterial strains poses a global health risk. In this scenario, alternative strategies are needed to combat the alarming rise in multidrug-resistant bacterial populations. For example, metal-incorporated graphene derivatives have emerged as model nanomaterials owing to their intrinsic antibacterial activity together with their biocompatibility. Interestingly, photon-activated phthalocyanine sensitizers have also shown promising physiochemical biocidal effects against pathogenic bacteria populations when conjugated with diverse nanomaterials. Herein, we report the facile synthesis of graphene oxide incorporated zinc phthalocyanine (ZnPc-GO) nanohybrids showing bactericidal activity against Gram-negative Escherichia coli (E. coli) cells, in the absence of any photo-excitation. The ZnPc-GO hybrid nanomaterials were synthesized by the in situ deposition of GO flakes on ZnPc-coated indium tin oxide (ITO) substrates. Two types of morphologically different ZnPc molecules, potato-chip-like α-phase ZnPc, namely ZnPc(A), and nanorod-like ß-phase ZnPc(B), were used for the synthesis of the ZnPc(A/B)-GO nanocomposites. The interactions of GO with the underlying ZnPc(A/B) entities in the ZnPc-GO systems were investigated using multiple characterization techniques. It was observed that the GO flakes in the ZnPc(B)-GO nanocomposite possess stronger π-π interactions and thus show a more efficient electron transfer mechanism when compared with the ZnPc(A) counterpart. Furthermore, the E. coli bacterial cells with an electronegative surface demonstrated a profound adherence to the electron-withdrawing ZnPc(B)-GO surface. The death kinetics of bacteria with ZnPc(B)-GO were further investigated using surface potential mapping and Kelvin probe force microscopy (KPFM) analysis. Upon direct contact with ZnPc(B)-GO, the adhered bacterial cells showed outer cell deformation and membrane protein leakage, induced by a proposed charge-transfer mechanism between negatively charged cells and the electron-withdrawing ZnPc(B)-GO surface. These new findings may provide insights into the design of potential ZnPc-GO-based novel antimicrobial nanomaterials or surface coatings.

Aromatase inhibitors in recurrent ovarian endometriomas: report of five cases with literature review.

OBJECTIVE: To determine the role of the aromatase inhibitor letrozole in the treatment of recurrent ovarian endometrioma cases. DESIGN: Nonrandomized proof of concept study. SETTINGS: Outpatient tertiary-care center. PATIENT(S): Five premenopausal patients with documented ovarian endometriomas and chronic pelvic pain, all of whom were previously treated with surgery and medicine with unsatisfactory results. INTERVENTION(S): Ovarian endometriomas were diagnosed by biopsy after laparoscopic ovarian cystectomy and subsequently treated with hormones. After a 6-month washout of endometriosis hormone therapies, women took letrozole (2.5 mg), one tablet of 0.15 mg of desogestrel, and 0.03 mg of ethinyl estradiol, calcium (1,200 mg), and vitamin D3 (800 IU) daily for 6 months. MAIN OUTCOME MEASURE(S): Size of endometriomas (monitored by ultrasound), assessment of pelvic pain (by visual analog scale), and bone density (DEXA scan). RESULT(S): Disappearance of ovarian endometrioma and reduction in pelvic pain in all cases at the end of 6 months. The size of ovarian endometriomas was reduced after 3 months. Pain scores decreased only after 1 month of treatment and continued decreasing in each treatment month. Overall, no significant change in bone density was detected. CONCLUSION(S): Letrozole given with combined pills achieved complete regression of recurrent endometriotic cysts and pain relief in all cases.

Availability and use of emergency obstetric care services in four districts of West Bengal, India.

Process indicators have been recommended for monitoring the availability and use of emergency obstetric care (EmOC) services. A health facility-based study was carried out in 2002 in four districts of West Bengal, India, to analyze these process indicators. Relevant records and registers for 2001 of all studied facilities in the districts were reviewed to collect data using a pre-designed schedule. The numbers of basic and comprehensive EmOC facilities were inadequate in all the four districts compared to the minimum acceptable level. Overall, 26.2% of estimated annual births took place in the EmOC facilities (ranged from 16.2% to 45.8% in 4 districts) against the required minimum of 15%. The rate of caesarean section calculated for all expected births in the population varied from 3.5% to 4.4% in the four districts with an overall rate of 4%, which is less than the minimum target of 5%. Only 29.9% of the estimated number of complications (which is 15% of all births) was managed in the EmOC facilities. The combined case-fatality rate in the basic/comprehensive EmOC facilities was 1.7%. Major obstetric complications contributed to 85.7% of maternal deaths, and pre-eclampsia/eclampsia was the most common cause. It can be concluded that all the process indicators, except proportion of deliveries in the EmOC facilities, were below the acceptable level. Certain priority measures, such as making facilities fully functional, effective referral and monitoring system, skill-based training, etc., are to be emphasized to improve the situation.

Malignant mixed mullerian tumour of the fallopian tube of heterologous variety--a case report.

A female aged 49 years presented with pain and progressive swelling of right lower abdomen. She was operated upon and gross examination revealed a proliferative growth in the fimbrial end of the right fallopian tube. Microscopically the tumour comprised of adenocarcinoma and component of spindle cell stromal sarcoma with areas of chondrosarcoma as heterologous element. A diagnosis of malignant mixed mullerian tumour of the fallopian tube, clinically FIGO stage III was made, which is extremely rare in available literature.